A commercial MRI-based deep learning algorithm for prostate cancer detection showed greater positive predictive value, despite its lower sensitivity, potentially allowing it to assist radiologists in biopsy planning.
1 September 2024 in Radiology: Artificial Intelligence
Background: The increase in multiparametric magnetic resonance imaging (mpMRI) examinations as a fundamental tool in prostate cancer (PCa) diagnostics raises the need for supportive computer-aided imaging analysis. Therefore, we evaluated the performance of a commercially available AI-based algorithm for prostate cancer detection and classification in a multi-center setting. Methods: Representative patients with 3T mpMRI between 2017 and 2022 at three different university hospitals were selected. Exams were read according to the PI-RADSv2.1 protocol and then assessed by an AI algorithm. Diagnostic accuracy for PCa of both human and AI readings were calculated using MR-guided ultrasound fusion biopsy as the gold standard. Results: Analysis of 91 patients resulted in 138 target lesions. Median patient age was 67 years (range: 49–82), median PSA at the time of the MRI exam was 8.4 ng/mL (range: 1.47–73.7). Sensitivity and specificity for clinically significant prostate cancer (csPCa, defined as ISUP ≥ 2) were 92%/64% for radiologists vs. 91%/57% for AI detection on patient level and 90%/70% vs. 81%/78% on lesion level, respectively (cut-off PI-RADS ≥ 4). Two cases of csPCa were missed by the AI on patient-level, resulting in a negative predictive value (NPV) of 0.88 at a cut-off of PI-RADS ≥ 3. Conclusions: AI-augmented lesion detection and scoring proved to be a robust tool in a multi-center setting with sensitivity comparable to the radiologists, even outperforming human reader specificity on both patient and lesion levels at a threshold of PI-RADS ≥3 and a threshold of PI-RADS ≥ 4 on lesion level. In anticipation of refinements of the algorithm and upon further validation, AI-detection could be implemented in the clinical workflow prior to human reading to exclude PCa, thereby drastically improving reading efficiency.
Purpose: The aim of this study was to evaluate the accuracy of prostate volume estimates calculated from the ellipsoid formula using the anteroposterior (AP) diameter measured on axial and sagittal images obtained through ultrasonography (US) and magnetic resonance imaging (MRI).Methods: This retrospective study included 456 patients with transrectal US and MRI from two university hospitals. Two radiologists independently measured the prostate gland diameters on US and MRI: AP diameters on axial and sagittal images, transverse, and longitudinal diameters on midsagittal images. The volume estimates, volumeax and volumesag, were calculated from the ellipsoid formula by using the AP diameter on axial and sagittal images, respectively. The prostate volume extracted from MRI-based whole-gland segmentation was considered the gold standard. The intraclass correlation coefficient (ICC) was used to evaluate the inter-method agreement between volumeax and volumesag, and agreement with the gold standard. The Wilcoxon signedrank test was used to analyze the differences between the volume estimates and the gold standard.Results: The prostate gland volume estimates showed excellent inter-method agreement, and excellent agreement with the gold standard (ICCs >0.9). Compared with the gold standard, the volume estimates were significantly larger on MRI and significantly smaller on US (P<0.001). The volume difference (segmented volume–volume estimate) was greater in patients with larger prostate glands, especially on US.Conclusion: Volumeax and volumesag showed excellent inter-method agreement and excellent agreement with the gold standard on both US and MRI. However, prostate volume was overestimated on MRI and underestimated on US.
PurposeThe amount of fibroglandular tissue (FGT) and background parenchymal enhancement (BPE) are evaluated as part of the BI-RADS reporting standard for the diagnosis of breast cancer in magnetic resonance imaging (MRI). BPE is associated with breast cancer risk and affects the diagnostic accuracy of breast MRI readings but is subject to very high inter-reader variability.ApproachWe developed a fully automatic observer-independent method to measure the amount of FGT and BPE based on breast, FGT, and lesion masks, which classifies each into four classes based on thresholds applied to those scores. This retrospective study involved 2840 patients from seven institutions for whom T1-weighted dynamic contrast-enhanced breast MRI sequences with and without fat suppression were acquired using 1.5 or 3T scanners. FGT and BPE assessments for model development and evaluation were performed according to the BI-RADS guidelines by radiologists from the respective institutions and by a radiographer if the assessments were missing.ResultsThe performance of the models was compared using four-class accuracy and a paired t-test (α=0.05). Our automatic classification of FGT and BPE in a multi-institutional setting achieved a four-class accuracy of 0.535 for FGT and 0.504 for BPE (random=0.25). The calibration of the classification thresholds for each site individually resulted in a significant improvement, reaching an accuracy of 0.669 (p<0.05) for FGT and 0.565 (p<0.05) for BPE. The area under curve of receiver operating characterstic (ROC-AUC) to classify FGT and BPE into low versus high is 0.883 for FGT and 0.757 for BPE when computed across all sites. The averaged per-site AUCs are 0.926 for FGT and 0.810 for BPE.ConclusionFGT and BPE classification perform significantly better when classification thresholds are selected per clinical site.